Volume 27, Number 1—January 2021
Research Letter
Postmortem Stability of SARS-CoV-2 in Nasopharyngeal Mucosa
Table
Patient no. | Age, y/sex | BMI, kg/m2 | Main autopsy finding | Disease duration, d | Postmortem interval, h† | Postmortem SARS-CoV-2 RNA load at admission, Ct‡ |
---|---|---|---|---|---|---|
1§ |
54/F |
29.6 |
Pneumonia |
5 |
11.92 |
29.86 |
2§ |
66/M |
25.3 |
Pneumonia |
ND |
32.03 |
24.22 |
3§ |
63/M |
37.3 |
Pulmonary embolism, pneumonia |
6 |
5.03 |
32.55 |
4§ |
70/M |
22.2 |
Pneumonia, bronchitis, respiratory failure |
6 |
7.48 |
18.97 |
5§ |
52/M |
38.8 |
Pulmonary embolism |
10 |
5.32 |
ND |
6§ |
90/F |
24.9 |
Pneumonia, aspiration |
13 |
19.35 |
29.52 |
7§ |
71/M |
ND |
Pneumonia, MODS |
ND |
7.87 |
50 |
8§ |
77/M |
33.2 |
Pneumonia |
18 |
5.08 |
50 |
9§ |
61/M |
32.3 |
Intracerebral hemorrhage, pneumonia |
ND |
4.37 |
ND |
10§ |
76/M |
37.7 |
Pneumonia, MODS, endocarditis, leukemia |
ND |
2.85 |
15.22 |
11§,¶ |
59/F |
22.2 |
Pneumonia, multiple myeloma |
18 |
5.67 |
18.55 |
12¶ |
83/F |
26.0 |
Pneumonia, non-Hodgkin lymphoma |
25 |
6.83 |
ND |
13¶ |
80/M |
28.5 |
Pulmonary embolism, pneumonia, myelofibrosis |
12 |
6.5 |
ND |
14¶ |
71/F |
29.0 |
Pneumonia, myelofibrosis |
25 |
12.1 |
ND |
15¶ |
84/F |
21.4 |
Pneumonia |
ND |
35.75 |
ND |
16¶ | 31/M | 20.6 | Pneumonia, germ cell tumor | ND | 9.08 | ND |
*Ct, cycle threshold; MODS, multiple organ dysfunction syndrome; ND, not determined; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
†Time of death until cooling at 4°C.
‡Negative results are reflected by Ct 50.
§Longitudinal cohort.
¶Virus isolation cohort (S. Pfefferle, unpub. data, https://doi.org/10.1101/2020.10.10.334458).
Page created: December 16, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.